ABIOMED (NASDAQ:ABMD) is one of the top-performing stocks in the MedTech space. The company is strong on solid guidance and widespread global exposure. 
athenahealth, Inc. (ATHN): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
Original post
Over the past year, shares of the company have rallied a whopping 125.3%, steering past the S&P 500 index’s gain of 9.9% and the industry’s 22.1%.
In the past 60 days, the Zacks Consensus Estimate for earnings per sharerose 1.6% to 64 cents per share. The company has a Zacks Rank #2 (Buy), which indicates expectations of outperformance in the near term.
The stock has a Growth Score of A as well, which buoy optimism. Notably, stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 handily beat other stocks.
Let’s find out whether the recent positive trend can help sustain the stock overthe long run.
What Makes It an Attractive Pick?
Impella Holds Promise
ABIOMED’s flagship product line, Impella, has continued to be a key growth catalyst. Itsfiscal third-quarter performance has also been pretty encouraging.
In the United States, the PCI and cardiogenic shock indications established new quarterly records. Outside the United States, revenues from Impella heart pumps totalled $17.3 million,up 94% year over year.
Furthermore, the company recently announced the receipt of FDA Pre-Market Approval (PMA) for its ImpellaCPheart pump with SmartAssist. Moreover, the Impella 2.5 and Impella CP heart-pumps havereceived PMA for expanded use.
Guidance Solid
Based on a strong thirdquarter, the company raised fiscal 2018 revenue guidance to $583 million from $565 to $575 million.
Also, the guidance for fiscal 2018 operating margin has been raised to 26% from the earlier 23% to 25%.
Global Exposure
The Impella support has been integrated in hospitals acrossGermany and Japan. In Germany Impella has treated 12% of the annual 25,000 potential patients.
In Japan, nineout of the 10 projected sites have been opened in 2018. These sites havegenerated $1.1 million inrevenues in the third quarter of fiscal 2018.
Other Key Picks
Other top-ranked stocks in the broader medical sector are athenahealth, Inc. (NASDAQ:ATHN) , Bio-Rad Laboratories, Inc. (NYSE:BIO) and Centene Corporation (NYSE:CNC) . Each of these stocks sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has an expected long-term growth rate of 17.7% and projected earnings per share growth rate of 21.5%.
Bio-Rad has an expected long-term growth rate of 20% and estimated earnings per share growth rate of 20%.
Centene has an expected long-term growth rate of 14.4% and projected earnings per share growth rate of 14.4%.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
athenahealth, Inc. (ATHN): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
Original post